In addition to confirming their partnership with GenScript, there is new information. The Patents Pending section had a handful that had not previously been disclosed:
"Pending Patent Applications
The Company has the following pending patents covering its anti-HIV monoclonal antibody technology:
- Pending Patent covering the recombinant of the Clone 3 antibody. This form of the Clone 3 antibody is prepared using the known amino acid sequence of the antibody in conjunction with a high producing CHO cell line for generating recombinant form of the monoclonal antibodies that will ultimately be used in patient application.
- Pending Patent coverage of small molecules (mini-peptides) for commercial use derived from the structure of the Clone 3 antibody for interrupting and preventing binding between the HIV virus and the human CD4+ cell. Coverage is directed to blocking peptides that bind to and neutralize the HIV virus, and Competitive peptides that bind to the target CD4+ cells at the point of virus access into the human cell to prevent infection.
- Pending Patent covering the proprietary methodology for producing fully human neutralizing monoclonal antibodies against infectious diseases, including Rabies, influenza A, influenza B, Tetanus, Diphtheria, HIV-2, Anthrax, Smallpox, H1N1 influenza, Herpes Zoster, Varicella Zoster and Ebola.
- Pending Patent covering the proprietary methodology for produced anti-antigen monoclonal antibodies to produce vaccines to achieve a broad and durable humoral protective antibody response against the corresponding infectious agent."
News 
Market Data 
Discover 
